Quantcast
Last updated on April 23, 2014 at 20:10 EDT

Latest BVA Stories

2013-05-22 23:01:26

Fewer veterans see VA disability claims progress through appeals process as Board of Veterans´ Appeals reports reduced workforce. Belleville, IL (PRWEB) May 22, 2013 Nearly 50,000 veterans appeals were received by the Board of Veterans´ Appeals (BVA) in fiscal year 2012, with even more–54,033–expected by fiscal year-end 2013. However, veterans may find themselves waiting longer for a decision as the agency reports reduced decisions and a reduced workforce, according to...

2010-10-27 09:00:00

WASHINGTON, Oct. 27 /PRNewswire/ -- This Veteran's Day, as the nation honors the brave men and women who have risked or given their lives for this country, the National Library Service for the Blind and Physically Handicapped (NLS), Library of Congress, stands ready to provide eligible veterans access to a free library service that promotes independence, wellness, and quality of life. "This November 11, as an expression of our deepest gratitude, we wish to remind these men and women who...

2009-10-21 11:02:00

Four New Judges Will Speed Veterans' Appeals WASHINGTON Oct. 21 /PRNewswire-USNewswire/ -- Secretary of Veterans Affairs Eric K. Shinseki announced the addition of four new Veterans Law Judges to the Board of Veterans' Appeals (BVA), which will enable the board to increase the number of cases being decided. "Veterans have earned the right to prompt, exhaustive and professional review of their claims for benefits," Secretary Shinseki said. "This expansion of BVA will enable Veterans to...

2009-09-09 08:00:00

CHARLOTTESVILLE, Virginia, September 9 /PRNewswire/ -- Biovista Inc. today announced that BVA-201, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-201 is an existing drug that Biovista repositioned in MS and is aimed at neuroprotection. It was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS. "This is our...

2009-04-02 08:00:00

CHARLOTTESVILLE, Virginia, April 2 /PRNewswire/ -- Biovista Inc. today announced that BVA-101, its drug targeting Multiple Sclerosis (MS), has shown significant positive results in the MOG-induced Experimental Allergic Encephalomyelitis (EAE) murine model of MS. BVA-101, an existing drug that Biovista repositioned in MS and is aimed at neuroprotection, was shown to have both efficacy in reducing symptoms and no toxic effects in this well established model of MS. "We are excited about...

2008-08-13 09:01:15

Daxor Corporation (AMEX: DXR), a medical instrumentation and biotechnology company, today announced a purchase by Union Hospital and a separate trial agreement for the Blood Volume Analyzer BVA-100. The purchase of the BVA-100 was received from Union Hospital of Elkton, Maryland. Since 1908, Union Hospital has provided quality health and wellness services to residents in Maryland, Delaware and Pennsylvania. As a 126-bed state-of-the-art not-for-profit hospital, Union Hospital is the...